Hanmi Pharm Signs $2.31 Billion License Deal for HM17321 with Genentech

MT Newswires Live

Aug 27

Hanmi Science (KRX:008930) said its unit Hanmi Pharm has signed a $2.31 billion license deal with Genentech, granting an exclusive license to research, develop, manufacture, and commercialize HM17321, a long-acting UCN2 analog, worldwide, excluding South Korea.

Under the deal, Hanmi Pharm will receive $190 million in upfront payments and is eligible for up to $2.12 billion in milestone payments tied to clinical development, regulatory approval, and commercialization, according to a Thursday filing with the Korean Exchange

Hanmi Pharm will also receive tiered royalties based on annual net sales following commercialization, and the deal is subject to applicable administrative procedures and administrative requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/2662102778"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662102778\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662102778?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 13:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662102778","market":"sg","top_or_hot":-1,"title":"Hanmi Pharm Signs $2.31 Billion License Deal for HM17321 with Genentech","media":"MT Newswires Live","content":"<html><body><p> Hanmi Science (KRX:008930) said its unit Hanmi Pharm has signed a $2.31 billion license deal with Genentech, granting an exclusive license to research, develop, manufacture, and commercialize HM17321, a long-acting UCN2 analog, worldwide, excluding South Korea.</p><p>Under the deal, Hanmi Pharm will receive $190 million in upfront payments and is eligible for up to $2.12 billion in milestone payments tied to clinical development, regulatory approval, and commercialization, according to a Thursday filing with the Korean Exchange</p><p>Hanmi Pharm will also receive tiered royalties based on annual net sales following commercialization, and the deal is subject to applicable administrative procedures and administrative requirements.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanmi Pharm Signs $2.31 Billion License Deal for HM17321 with Genentech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanmi Pharm Signs $2.31 Billion License Deal for HM17321 with Genentech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-27 13:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hanmi Science (KRX:008930) said its unit Hanmi Pharm has signed a $2.31 billion license deal with Genentech, granting an exclusive license to research, develop, manufacture, and commercialize HM17321, a long-acting UCN2 analog, worldwide, excluding South Korea.</p><p>Under the deal, Hanmi Pharm will receive $190 million in upfront payments and is eligible for up to $2.12 billion in milestone payments tied to clinical development, regulatory approval, and commercialization, according to a Thursday filing with the Korean Exchange</p><p>Hanmi Pharm will also receive tiered royalties based on annual net sales following commercialization, and the deal is subject to applicable administrative procedures and administrative requirements.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662102778","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662102778","pubTimestamp":1787809539,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hanmi Science  said its unit Hanmi Pharm has signed a $2.31 billion license deal with Genentech, granting an exclusive license to research, develop, manufacture, and commercialize HM17321, a long-acting UCN2 analog, worldwide, excluding South Korea.Under the deal, Hanmi Pharm will receive $190 million in upfront payments and is eligible for up to $2.12 billion in milestone payments tied to clinical development, regulatory approval, and commercialization, according to a Thursday filing with the Korean ExchangeHanmi Pharm will also receive tiered royalties based on annual net sales following commercialization, and the deal is subject to applicable administrative procedures and administrative requirements.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","HAFC":"韩美金融"},"translate_title":"韩美制药与基因泰克签署价值 23.1 亿美元的 HM17321 许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAFC":1.5},"content_text":"Hanmi Science (KRX:008930) said its unit Hanmi Pharm has signed a $2.31 billion license deal with Genentech, granting an exclusive license to research, develop, manufacture, and commercialize HM17321, a long-acting UCN2 analog, worldwide, excluding South Korea.Under the deal, Hanmi Pharm will receive $190 million in upfront payments and is eligible for up to $2.12 billion in milestone payments tied to clinical development, regulatory approval, and commercialization, according to a Thursday filing with the Korean ExchangeHanmi Pharm will also receive tiered royalties based on annual net sales following commercialization, and the deal is subject to applicable administrative procedures and administrative requirements.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}